NPPA seeks clarification on Gilead's drug pricing plea
National Pharmaceutical Pricing Authority has sought clarifications
from the company. Gilead had sought exemption from price control for
its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a
major chunk of Rs 140-crore market for chronic Hepatitis B in India.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms
from the company. Gilead had sought exemption from price control for
its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a
major chunk of Rs 140-crore market for chronic Hepatitis B in India.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-seeks-clarification-on-gileads-drug-pricing-plea/articleshow/73788094.cms
Comments
Post a Comment